Lantern Pharma Inc.
LTRN
$3.62
-$0.18-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.92M | -19.25M | -19.88M | -20.78M | -19.09M |
| Total Depreciation and Amortization | 211.40K | 161.50K | 112.30K | 64.00K | 177.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 745.00K | 370.40K | 478.30K | 676.00K | -105.80K |
| Change in Net Operating Assets | 1.11M | 850.00K | 166.50K | 2.23M | 1.79M |
| Cash from Operations | -16.86M | -17.87M | -19.12M | -17.81M | -17.23M |
| Capital Expenditure | -4.90K | -7.30K | -11.60K | -12.60K | -14.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.21M | 10.97M | 7.18M | 3.38M | 192.90K |
| Cash from Investing | 16.21M | 10.96M | 7.16M | 3.37M | 178.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 971.80K | 12.00K | 12.00K | 66.70K | 66.70K |
| Repurchase of Common Stock | -- | -- | -- | -- | -500.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 971.80K | 12.00K | 12.00K | 66.70K | -433.30K |
| Foreign Exchange rate Adjustments | -36.80K | -20.30K | -36.90K | -49.50K | 12.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 286.70K | -6.92M | -11.98M | -14.43M | -17.47M |